Product Description
A potent and selective small molecule oral inhibitor of the SOS1 and RAS interaction. In KRAS G12C mutant cells, BAY 3498264 inhibits the rebound of phospho-ERK induced by sotorasib, achieving a more prolonged ERK phosphorylation inhibition when combined. Additionally, in in vitro proliferation assays, combining BAY 3498264 with various MAPK pathway inhibitors demonstrates marked combination effect as compared to single agent MAPK inhibition. The combination of BAY 3498264 with sotorasib in KRAS G12C mutant CDX and PDX models in vivo is well tolerated and exhibits combination benefit, enhancing both the depth and duration of response over sotorasib alone. (Sourced from: https://aacrjournals.org/cancerres/article/85/8_Supplement_1/4373/760909)
Mechanisms of Action: SOS1 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Bayer
Company Location:
Company Founding Year: 1863
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Denmark, Italy, Spain, United Kingdom
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Heart Block|Heart Cancer
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06659341 |
NCT06659341 | P1 |
Recruiting |
Heart Cancer|Heart Block |
2027-04-26 |
12% |
2026-08-27 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
01/14/2025 |
News Article |
Bayer's Pharma Growth Strategy Progressing Well as Pipeline Advances |